Table of Contents: What should I know before receiving my first Ozempic shot
View image online ( Patient holding injectable Use of GLP-1 receptor agonistswith or without glucose-dependent insulinotropic polypeptide (GIP)may be associated with improved clinical outcomes in patients with Type 1 diabetes, according to a large retrospective analysis published in Diabetes Technology & Therapeutics
71% stop taking GLP-1s by 12 months 6 74% report gastrointestinal symptoms 7 65% report NO increased exercise after starting medication 8 This is why the Noom GLP-1 Rx Program with Noom GLP-1 Companion exists
Our study supports the efficacy of GLP-1 RAs in reducing cardiovascular events among individuals with concurrent type 2 diabetes and AKD, highlighting their role in the complex management of these comorbid conditions
In 2017, a post hoc pooled analysis of RCTs on liraglutide demonstrated comparably low incidences of depression and anxiety in both the liraglutide and placebo cohorts
It is essential to be critical of unverified information you read online, follow evidence-based approaches, and discuss the pros and cons of microdosing with your healthcare provider before making a choice